Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel
10 Janvier 2022 - 1:30PM
Avicanna USA Inc. together with Avicanna Inc.
("
Avicanna" or the "
Company")
(TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company
focused on the development, manufacturing, and commercialization of
organic and sustainable plant-derived cannabinoid-based products,
is pleased to announce the appointment of Stephen Kim as the
Avicanna’s Chief Legal Officer & General Counsel.
Mr. Kim comes with over twenty years of legal
experience with highly regulated and innovative industries. He has
significant pharmaceutical industry experience and is very familiar
with the complex overlay of corporate, commercial, IP, governance,
compliance, and regulatory considerations associated with
development, approval, and launch of multiple pharmaceutical
products, which he has executed in the US, Canada, and
globally.
Prior to joining Avicanna, Mr. Kim held various
roles of progressive responsibility at global biotechnology and
pharmaceutical companies including Bayer Inc., Celgene Corporation,
and Indivior Inc., and also held roles as an associate with leading
US and International law firms in New York City and Toronto. Mr.
Kim graduated with a US law degree from University of Detroit Mercy
(JD) and a Canadian law degree from the University of Windsor
(LLB).
“I am delighted to be joining Avicanna at such
an exciting time and looking forward to partnering and working with
the dynamic and visionary Management Team and with the accomplished
and experienced members of the Board of Directors.” Stephen Kim
commented, “With my background and experience in domestic and
cross-border transactions, as well as pharmaceutical product
development, approval, and launch, I am particularly excited about
the Company’s work in the areas of evidence-based and
pharmaceutical products and global business.”
“We are thrilled to bring someone of Mr. Stephen
Kim’s calibre onboard as we evolve into the next phase of
commercialization and development of our pharmaceutical pipeline.
Stephen’s experience and track record coupled with his alignment of
vision with the Management Team is precisely what the Company needs
to achieve its growth potential,” Aras Azadian, Chief Executive
Officer, commented.
Mr. Kim will join the Company at his role as the
Chief Legal Officer on January 17, 2022, where he will oversee all
legal and regulatory affairs at a global level.
About Avicanna
Avicanna is a Canadian commercial-stage
biopharmaceutical company established in cannabinoid research,
development, and evidence-based products for the global consumer,
as well as medical and pharmaceutical market segments. In leading
global cannabinoid advancements, Avicanna conducts most of its
research in Canada at its R&D headquarters in the Johnson &
Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS
Discovery District. The company actively collaborates with leading
Canadian academic and medical institutions. Avicanna has
established an industry-leading scientific platform including
advanced R&D and clinical development which has led to the
commercialization of over twenty products across four main market
segments:
- Medical Cannabis
& Wellness Products: Marketed under the RHO Phyto™ brand, or
Magisterial Preparations, these medical and wellness products are
an advanced line of pharmaceutical-grade cannabis products
containing varying ratios of cannabidiol (“CBD”) and
tetrahydrocannabinol (“THC”). The product portfolio contains a full
formulary of products including oral, sublingual, topical, and
transdermal deliveries that have controlled dosing, enhanced
absorption and stability studies supported by pre-clinical data.
The advanced formulary is marketed with consumer, patient and
medical community education and training. Avicanna’s medical and
wellness product portfolio also forms the foundation of the
Company’s pharmaceutical pipeline with the contribution of the
formulations that form the basis of the products as well as the
data generated from sales and participation of the products in real
world evidence studies.
- CBD
Derma-Cosmetic Products: Marketed under the Pura H&W™ or Pura
Earth™ brands, these registered, clinically tested, derma-cosmetic
products include a portfolio of functional CBD topical
products.
- Pharmaceutical
Pipeline: Leveraging Avicanna’s scientific platform, vertical
integration, and real-world evidence, Avicanna has created a
pipeline of patent-pending drug candidates which are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates
provide solutions for unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (Trunerox) is in the
drug registration stage in South America.
- Cannabis Raw
Materials, Seeds, and Bulk Formulations: Marketed under the Aureus™
brand, the Company’s raw material business has successfully
completed sales to 11 countries. Aureus offers cannabis dried
flower, standardized seeds, full spectrum extracts, and cannabinoid
distillates, isolated cannabinoids (CBD, THC, cannabigerol (“CBG”)
and other rare cannabinoids), and bulk formulations derived from
hemp and cannabis cultivars through its sustainable, economical,
and industrial-scale subsidiaries based in Colombia. The majority
of the Aureus products are produced at Santa Marta Golden Hemp
S.A.S. (“SMGH”), the Company’s majority-owned subsidiary, which is
also Good Agricultural and Collection Practices (“GACP”) certified
and has United States Department of Agriculture (“USDA”) National
Organic Program certification for its hemp cultivar.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at info@avicanna.com
or follow us on social media on LinkedIn, Twitter, Facebook or
Instagram.
The Company posts updates through videos from
the official company YouTube channel
https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.
Cautionary Note Regarding
Forward-Looking Information and StatementsThis news
release contains "forward-looking information" within the meaning
of applicable securities laws. Forward-looking information
contained in this press release may be identified by the use of
words such as, "may", "would", "could", "will", "likely", "expect",
"anticipate", "believe, "intend", "plan", "forecast", "project",
"estimate", "outlook" and other similar expressions.
Forward-looking information is not a guarantee of future
performance and is based upon a number of estimates and assumptions
of management in light of management's experience and perception of
trends, current conditions and expected developments, as well as
other factors relevant in the circumstances, including assumptions
in respect of current and future market conditions, the current and
future regulatory environment, the availability of licenses,
approvals and permits, and the utility and potential application of
certain drugs, cannabinoids, compounds and products. Although the
Company believes that the expectations and assumptions on which
such forward looking information is based are reasonable, undue
reliance should not be placed on the forward looking information
because the Company can give no assurance that they will prove to
be correct. Actual results and developments may differ materially
from those contemplated by these statements. Forward-looking
information is subject to a variety of risks and uncertainties that
could cause actual events or results to differ materially from
those projected in the forward-looking information. Such risks and
uncertainties include, but are not limited to current and future
market conditions, including the market price of the common shares
of the Company, and the risk factors set out in the Company's
annual information form dated September 3, 2021 and final short
form prospectus dated November 27, 2020, filed with the Canadian
securities regulators and available under the Company's profile on
SEDAR at www.sedar.com. The statements in this press release are
made as of the date of this release. The Company disclaims any
intent or obligation to update any forward-looking information,
whether as a result of new information, future events or results or
otherwise, other than as required by applicable securities
laws.
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024